



BSW Formulary Updates and Recent Decisions – December 2024

(Virtual decisions reached in the absence of a full APC meeting)

New additions to BSWformulary and Change in Traffic Light Status (TLS)

- [Pylera® capsules \(140mg bismuth subcitrate potassium, 125mg metronidazole and 125mg tetracycline hydrochloride\)](#) for the treatment/eradication of H pylori infection in conjunction with omeprazole with GREEN TLS.
- [Vaginal pessaries](#) (plastic and silicone) entry now published.
- **Change in TLS - [Camellia Seinensis \(Catephen®\)](#)** for the treatment of external genital warts changed from RED to GREEN in view of shortages of alternative options.

New and Updated Prescribing Guidelines and Shared Care Agreements

- **UPDATE – [Lidocaine Plaster Guidance](#)** reference to Ralvo® brand removed, following its discontinuation, and suggests prescribing should be generic.
- **NEW – [Relugolix Guidance](#)** for treating hormone-sensitive prostate cancer to support implementation of NICE TA995.
- **UPDATE – [BSW Guidance for Prescribing Hayfever and Allergic Rhinitis](#)** link to Flixonase nasules removed following discontinuation, links and prices corrected and updated. Budesonide and beclomethasone to state for children over 6 years.
- **UPDATE – [Ibandronic acid for Postmenopausal Women with Early Breast Cancer Shared Care Agreement](#)** updated to include use at SFT and update costs and contact details.

Minor amendments to Netformulary

- Zostavax shingles vaccine moved to non-formulary, unavailable
- Bromocriptine 1mg removed from formulary as no longer available
- Freestyle Libre 2 moved to non-formulary, to be replaced with Freestyle Libre 2+
- Emerade moved to non-formulary as discontinued
- Primidone 125mg tablets additional indication of epilepsy
- Added link to MSN for Neutrogena T/Gel therapeutic 2% shampoo as it is being discontinued in Feb 25. Moved to non-formulary section.

What the BSW ICB formulary team are currently working on

- Updating HRT guidance and reviewing the use of testosterone in women shared care agreement.
- Updating the erectile dysfunction guidance
- Updating the asthma guidance for adults & children
- Updating the over-active bladder guidance

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net